AI Portfolio Summary
In 2025 Q4, ORBIMED ADVISORS LLC maintained a portfolio of 133 distinct positions. The most significant new addition to the portfolio was BRISTOL-MYERS SQUIBB, which now represents 0.85% of the total fund value. They heavily accumulated shares in EDWARDS LIFESCIENCES, increasing their position by 9.4%. The fund also reduced its exposure to TERNS PHARMACEUTICAL by 71.5%.
Total Positions
133
Quarter
2025 Q4
Top Holding
EWTX (7.9%)
Top 10 Concentration
40.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 133
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 7.86% | 5.92% |
#1
Prev: #1
|
6.1 | no change | no change |
P
S
|
15,518,492 | $385,091,379 |
$30.54
-22.8%
|
2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
LLY
ELI LILLY & CO
|
Healthcare | 6.61% | 5.40% |
#2
1
Prev: #3
|
5.1 | no change | no change |
P
S
|
301,200 | $323,693,616 |
$59.81
+1638.4%
|
2001 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
BSX
BOSTON SCIENTIF...
|
Healthcare | 4.71% | 5.57% |
#3
1
Prev: #2
|
3.4 | -10,000 | -0.4% |
P
S
|
2,419,300 | $230,680,255 |
$28.78
+231.8%
|
2006 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
SVA
SINOVAC BIOTECH...
|
Unknown | 3.77% | 4.33% |
#4
Prev: #4
|
3.0 | no change | no change |
P
S
|
2,718,735 | $184,466,170 | 2011 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EW
EDWARDS LIFESCI...
|
Healthcare | 3.21% | 3.08% |
#5
3
Prev: #8
|
3.8 | 158,900 | 9.4% |
P
S
|
1,842,900 | $157,107,225 | 2011 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UPB
UPSTREAM BIO IN...
|
Healthcare | 3.16% | 2.52% |
#6
6
Prev: #12
|
2.3 | no change | no change |
P
S
|
5,693,589 | $154,580,941 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ISRG
INTUITIVE SURGI...
|
Healthcare | 3.04% | 3.02% |
#7
2
Prev: #9
|
1.7 | -23,800 | -8.3% |
P
S
|
263,400 | $149,179,224 | 2010 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SION
SIONNA THERAPEU...
|
Healthcare | 2.99% | 2.56% |
#8
3
Prev: #11
|
1.7 | -143,304 | -3.9% |
P
S
|
3,561,655 | $146,526,487 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 2.53% | 1.65% |
#9
8
Prev: #17
|
1.5 | -67,684 | -1.7% |
P
S
|
3,935,203 | $124,116,303 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARGX
ARGENX SE
|
Healthcare | 2.51% | 2.99% |
#10
Prev: #10
|
1.5 | -26,300 | -15.3% |
P
S
|
146,000 | $122,778,700 | 2017 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 2.50% | 3.83% |
#11
6
Prev: #5
|
2.0 | no change | no change |
P
S
|
7,959,538 | $122,576,885 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALNY
ALNYLAM PHARMAC...
|
Healthcare | 2.34% | 3.23% |
#12
6
Prev: #6
|
1.4 | -12,800 | -4.2% |
P
S
|
288,800 | $114,841,320 | 2010 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYK
STRYKER CORPORA...
|
Healthcare | 2.33% | 3.12% |
#13
6
Prev: #7
|
1.4 | -34,200 | -9.5% |
P
S
|
325,000 | $114,227,750 | 2006 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SPRY
ARS PHARMACEUTI...
|
Healthcare | 1.97% | 1.96% |
#14
1
Prev: #15
|
1.8 | no change | no change |
P
S
|
8,288,510 | $96,561,142 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 1.78% | 1.33% |
#15
6
Prev: #21
|
0.7 | -5,409,671 | -71.5% |
P
S
|
2,153,300 | $86,993,320 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 1.73% | 2.20% |
#16
3
Prev: #13
|
0.7 | -347,470 | -24.6% |
P
S
|
1,067,550 | $84,774,146 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CAI
CARIS LIFE SCIE...
|
Healthcare | 1.72% | 2.16% |
#17
3
Prev: #14
|
1.2 | 81,153 | 2.7% |
P
S
|
3,116,011 | $84,069,977 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTRA
NATERA INC
|
Healthcare | 1.71% | 1.62% |
#18
1
Prev: #19
|
1.2 | -63,500 | -14.8% |
P
S
|
365,800 | $83,801,122 | 2015 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPX
COMPASS THERAPE...
|
Healthcare | 1.67% | 1.25% |
#19
6
Prev: #25
|
1.7 | no change | no change |
P
S
|
15,219,994 | $81,731,368 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 1.65% | 0.75% |
#20
20
Prev: #40
|
1.2 | 22,503 | 2.0% |
P
S
|
1,161,803 | $80,803,399 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DHR
DANAHER CORPORA...
|
Healthcare | 1.40% | 1.23% |
#21
7
Prev: #28
|
2.6 | 36,700 | 13.9% |
P
S
|
299,800 | $68,630,216 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 1.29% | 1.63% |
#22
4
Prev: #18
|
1.0 | -210,300 | -12.2% |
P
S
|
1,516,550 | $62,967,156 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLS
APELLIS PHARMAC...
|
Healthcare | 1.25% | 1.24% |
#23
4
Prev: #27
|
1.0 | 106,500 | 4.6% |
P
S
|
2,429,868 | $61,038,284 | 2018 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 1.24% | 1.31% |
#24
2
Prev: #22
|
1.5 | no change | no change |
P
S
|
3,027,328 | $60,909,839 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CI
THE CIGNA GROUP
|
Healthcare | 1.15% | 1.10% |
#25
6
Prev: #31
|
3.0 | 42,200 | 25.9% |
P
S
|
205,000 | $56,422,150 | 2009 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 1.14% | 0.66% |
#26
18
Prev: #44
|
3.5 | 556,273 | 51.2% |
P
S
|
1,642,891 | $55,644,718 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 1.13% | 1.24% |
#27
1
Prev: #26
|
1.5 | no change | no change |
P
S
|
7,165,006 | $55,170,546 | 2016 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 1.05% | 1.13% |
#28
2
Prev: #30
|
0.9 | -9,700 | -8.4% |
P
S
|
105,200 | $51,258,700 | 2008 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 1.01% | 0.76% |
#29
10
Prev: #39
|
0.9 | -12,100 | -3.2% |
P
S
|
367,900 | $49,613,155 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 0.97% | 0.97% |
#30
5
Prev: #35
|
0.9 | -523,891 | -19.3% |
P
S
|
2,190,907 | $47,542,682 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 0.95% | 1.08% |
#31
1
Prev: #32
|
0.9 | -100,000 | -9.1% |
P
S
|
999,000 | $46,503,450 | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AXSM
AXSOME THERAPEU...
|
Healthcare | 0.94% | 1.52% |
#32
12
Prev: #20
|
0.4 | -278,679 | -52.4% |
P
S
|
253,121 | $46,230,019 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EYPT
EYEPOINT INC
|
Healthcare | 0.92% | 0.60% |
#33
15
Prev: #48
|
2.9 | 672,314 | 37.4% |
P
S
|
2,468,314 | $45,096,097 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RNA
AVIDITY BIOSCIE...
|
Healthcare | 0.91% | 1.68% |
#34
18
Prev: #16
|
0.4 | -1,019,356 | -62.2% |
P
S
|
619,530 | $44,686,699 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 0.91% | 1.17% |
#35
6
Prev: #29
|
0.9 | -39,400 | -11.1% |
P
S
|
314,240 | $44,568,659 | 2012 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 0.88% | 0.69% |
#36
7
Prev: #43
|
0.9 | -112,000 | -4.8% |
P
S
|
2,202,184 | $43,074,719 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMY
BRISTOL-MYERS S...
|
Healthcare | 0.85% | — |
#37
Prev: #—
|
3.8 | 775,000 | no change |
NEW
|
775,000 | $41,803,500 | 2007 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PFE
PFIZER INC
|
Healthcare | 0.84% | — |
#38
Prev: #—
|
3.8 | 1,652,900 | no change |
NEW
|
1,652,900 | $41,157,210 | 2001 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 0.82% | 0.71% |
#39
2
Prev: #41
|
0.8 | -117,700 | -3.6% |
P
S
|
3,190,700 | $39,947,564 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NPCE
NEUROPACE INC
|
Healthcare | 0.76% | 0.63% |
#40
6
Prev: #46
|
0.8 | -207,849 | -8.0% |
P
S
|
2,406,335 | $37,153,812 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 0.75% | 0.90% |
#41
5
Prev: #36
|
0.8 | -19,928 | -10.4% |
P
S
|
171,977 | $36,672,375 | 2015 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EXAS
EXACT SCIENCES ...
|
Healthcare | 0.73% | 1.28% |
#42
18
Prev: #24
|
0.3 | -642,900 | -64.6% |
P
S
|
351,716 | $35,720,277 | 2011 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 0.73% | 1.31% |
#43
20
Prev: #23
|
0.3 | -489,094 | -33.3% |
P
S
|
980,400 | $35,578,716 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELV
ELEVANCE HEALTH...
|
Healthcare | 0.71% | — |
#44
Prev: #—
|
3.8 | 99,100 | no change |
NEW
|
99,100 | $34,739,505 | 2014 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FBRX
FORTE BIOSCIENC...
|
Healthcare | 0.67% | 0.42% |
#45
11
Prev: #56
|
1.3 | no change | no change |
P
S
|
1,196,955 | $32,640,963 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRLD
PRELUDE THERAPE...
|
Healthcare | 0.65% | 0.37% |
#46
15
Prev: #61
|
1.3 | no change | no change |
P
S
|
10,909,256 | $31,636,842 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYBN
CYBIN INC
|
Healthcare | 0.64% | — |
#47
Prev: #—
|
3.8 | 3,840,500 | no change |
NEW
|
3,840,500 | $31,415,290 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORIC
ORIC PHARMACEUT...
|
Healthcare | 0.61% | 1.03% |
#48
15
Prev: #33
|
1.2 | no change | no change |
P
S
|
3,641,756 | $29,789,564 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRYS
KRYSTAL BIOTECH...
|
Healthcare | 0.60% | 0.43% |
#49
6
Prev: #55
|
2.2 | 17,055 | 16.6% |
P
S
|
119,800 | $29,535,492 | 2019 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 0.57% | — |
#50
Prev: #—
|
3.7 | 94,500 | no change |
NEW
|
94,500 | $27,852,930 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 133 holdings